Dual PPARγ and EGF Receptor Targeting Compounds
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for tumors expressing PPARγ and EGF receptors, as well as chronic inflammatory diseases, lack effective agents that can simultaneously target these receptors for anti-inflammatory and anti-tumor actions.
Innovation Solution
Development of novel compounds that modulate PPARγ and EGF receptors, specifically designed to inhibit cellular proliferation, induce apoptosis, and reduce inflammation, including specific pharmaceutical compositions and methods for their use in treating various cancers and inflammatory diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If current treatments are used for tumors expressing PPARγ and EGF receptors, then existing therapeutic options are available, but effective agents that can simultaneously target these receptors for anti-inflammatory and anti-tumor actions are lacking
Solution Approach 1:
The patent applies the universality principle by designing compound (I) to simultaneously target multiple receptors (PPARγ and EGF receptors) with a single molecular structure. The compound contains specific functional groups (amino group at position 3 or 4, hydroxyl or alkoxy groups) that enable dual receptor binding, allowing one agent to perform multiple therapeutic functions: anti-tumor activity through EGF receptor inhibition and anti-inflammatory activity through PPARγ activation, thereby resolving the limitation of current single-target treatments
2Adaptability or versatility
If novel compounds are designed to simultaneously target PPARγ and EGF receptors, then multi-functional therapeutic action is achieved, but the complexity of compound design and synthesis increases
Solution Approach 1:
The patent merges the functional requirements for PPARγ activation and EGF receptor inhibition into a single compound (I) structure. The molecular design combines an aromatic ring system with specific substituents (amino group at position 3 or 4, and hydroxyl or alkoxy groups) that collectively provide both PPARγ binding affinity and EGF receptor inhibition capability, reducing the need for multiple separate medications while managing structural complexity through systematic molecular design
3Reliability
If compounds are developed to inhibit cellular proliferation and induce apoptosis, then anti-tumor efficacy is improved, but the risk of off-target effects and toxicity increases
Solution Approach 1:
The patent employs feedback control through the dual-receptor mechanism where PPARγ activation provides a regulatory counterbalance to EGF receptor inhibition. PPARγ activation promotes anti-inflammatory effects and cellular homeostasis, which feedback to modulate the anti-proliferative and pro-apoptotic effects of EGF receptor inhibition, thereby enhancing anti-tumor efficacy while reducing off-target toxicity through coordinated receptor signaling
Data Source
AI summary
The present invention relates to compounds comprising the general formula (I), in which R1 and R2, which may be identical or different, are selected from the group comprising —H or a linear or branched alkyl group having from 1 to 6 carbon atoms or together form an aromatic or aliphatic ring with 5 or 6 atoms; Y and Z, which may be identical or different, are selected from the group comprising —H, —OH, —COOH, —OR3, —CH(OR3)COOH, in which R3 is selected from H, phenyl, benzyl, —CF3 or —CF2CF3, vinyl, allyl and a linear or branched alkyl group having from 1 to 6 carbon atoms.